Skip to main content
Erschienen in: Journal of Neural Transmission 12/2017

02.09.2017 | Neurology and Preclinical Neurological Studies - Original Article

Levels of amyloid-beta-42 and CSF pressure are directly related in patients with Alzheimer’s disease

verfasst von: Tommaso Schirinzi, Giulia Di Lazzaro, Giulia Maria Sancesario, Vito Luigi Colona, Eugenia Scaricamazza, Nicola Biagio Mercuri, Alessandro Martorana, Giuseppe Sancesario

Erschienen in: Journal of Neural Transmission | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Abstract

Experimental data suggest that the cerebrospinal fluid (CSF) dynamic is involved in the clearance of beta-amyloid, a key event in the pathogenesis of Alzheimer’s disease (AD). At this regard no evidence still exists in vivo. In this study we explored the relationships between CSF pressure and AD pathology, as measured with CSF core biomarkers. We enrolled 16 patients with probable AD and 21 controls, collecting demographics, clinical data, CSF opening pressure and CSF levels of beta-amyloid-42 fragment (Aβ42), total-tau (t-tau), phosphorylated-tau-181 (p-tau), albumin and albumin ratio. Differences between the groups were calculated with non-parametric tests, while correlations among all parameters were separately calculated with Spearman’s test in each group. The groups significantly differed in biomarkers’ concentration with lower Aβ42, and higher t-tau and p-tau in AD patients. Moreover, CSF pressure was significantly lower in AD group (11.0 ± 2.8 vs. 13.3 ± 3.0 mmHg, p < 0.05) and directly correlated with Aβ42 levels (R = 0.512; p < 0.05), but not with other biomarkers or parameters. No significant correlations emerged for biomarkers in control group. AD patients exhibit low CSF pressure whose values are directly and selectively related to CSF Aβ42 levels. This interesting correlation may confirm in vivo the association between CSF dynamic and beta-amyloid metabolism occurring in AD.
Literatur
Zurück zum Zitat Bell RD, Zlokovic BV (2009) Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer’s disease. Acta Neuropathol 118(1):103–113CrossRefPubMedPubMedCentral Bell RD, Zlokovic BV (2009) Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer’s disease. Acta Neuropathol 118(1):103–113CrossRefPubMedPubMedCentral
Zurück zum Zitat Blennow K et al (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Publ Group 6(3):131–144 Blennow K et al (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Publ Group 6(3):131–144
Zurück zum Zitat Blennow K et al (2016) Cerebrospinal fluid biomarkers in Alzheimer’s and Parkinson’s diseases—from pathophysiology to clinical practice. Mov Disord 31(6):836–847CrossRefPubMed Blennow K et al (2016) Cerebrospinal fluid biomarkers in Alzheimer’s and Parkinson’s diseases—from pathophysiology to clinical practice. Mov Disord 31(6):836–847CrossRefPubMed
Zurück zum Zitat Dorr A et al (2012) Amyloid-β-dependent compromise of microvascular structure and function in a model of Alzheimer’s disease. Brain 135(Pt 10):3039–3050CrossRefPubMed Dorr A et al (2012) Amyloid-β-dependent compromise of microvascular structure and function in a model of Alzheimer’s disease. Brain 135(Pt 10):3039–3050CrossRefPubMed
Zurück zum Zitat Dubois B et al (2007) Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6(8):734–746CrossRefPubMed Dubois B et al (2007) Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6(8):734–746CrossRefPubMed
Zurück zum Zitat Friedman DI, Liu GT, Digre KB (2013) Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology 81(13):1159–1165CrossRefPubMed Friedman DI, Liu GT, Digre KB (2013) Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology 81(13):1159–1165CrossRefPubMed
Zurück zum Zitat Iadecola C (2003) Cerebrovascular effects of amyloid-beta peptides: mechanisms and implications for Alzheimer’s dementia. Cell Mol Neurobiol 23(4–5):681–689CrossRefPubMed Iadecola C (2003) Cerebrovascular effects of amyloid-beta peptides: mechanisms and implications for Alzheimer’s dementia. Cell Mol Neurobiol 23(4–5):681–689CrossRefPubMed
Zurück zum Zitat Iliff JJ et al (2012) A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid. Sci Transl Med 4(147):147ra111CrossRefPubMedPubMedCentral Iliff JJ et al (2012) A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid. Sci Transl Med 4(147):147ra111CrossRefPubMedPubMedCentral
Zurück zum Zitat Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10(9):698–712CrossRefPubMed Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10(9):698–712CrossRefPubMed
Zurück zum Zitat Li H et al (2014) Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: interplay with cerebral blood flow. Mol Neurodegener 9(1):28CrossRefPubMedPubMedCentral Li H et al (2014) Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: interplay with cerebral blood flow. Mol Neurodegener 9(1):28CrossRefPubMedPubMedCentral
Zurück zum Zitat Martorana A et al (2015) Cerebrospinal fluid Aβ42 levels: when physiological become pathological state. CNS Neurosci Ther 21(12):921–925CrossRefPubMed Martorana A et al (2015) Cerebrospinal fluid Aβ42 levels: when physiological become pathological state. CNS Neurosci Ther 21(12):921–925CrossRefPubMed
Zurück zum Zitat Preston SD et al (2003) Capillary and arterial cerebral amyloid angiopathy in Alzheimer’s disease: defining the perivascular route for the elimination of amyloid beta from the human brain. Neuropathol Appl Neurobiol 29(2):106–117CrossRefPubMed Preston SD et al (2003) Capillary and arterial cerebral amyloid angiopathy in Alzheimer’s disease: defining the perivascular route for the elimination of amyloid beta from the human brain. Neuropathol Appl Neurobiol 29(2):106–117CrossRefPubMed
Zurück zum Zitat Sagare AP, Bell RD, Zlokovic BV (2013) Neurovascular defects and faulty amyloid-β vascular clearance in Alzheimer’s disease. J Alzheimer’s Dis 33(Suppl 1):S87–S100 Sagare AP, Bell RD, Zlokovic BV (2013) Neurovascular defects and faulty amyloid-β vascular clearance in Alzheimer’s disease. J Alzheimer’s Dis 33(Suppl 1):S87–S100
Zurück zum Zitat Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM (2016) Alzheimer’s disease. Lancet 388(10043):505–517CrossRefPubMed Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM (2016) Alzheimer’s disease. Lancet 388(10043):505–517CrossRefPubMed
Zurück zum Zitat Schirinzi T et al (2015) A clinical and biochemical analysis in the differential diagnosis of idiopathic normal pressure hydrocephalus. Front Neurol 6:86CrossRefPubMedPubMedCentral Schirinzi T et al (2015) A clinical and biochemical analysis in the differential diagnosis of idiopathic normal pressure hydrocephalus. Front Neurol 6:86CrossRefPubMedPubMedCentral
Zurück zum Zitat Silverberg GD et al (2001) The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer’s type. Neurology 57(10):1763–1766CrossRefPubMed Silverberg GD et al (2001) The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer’s type. Neurology 57(10):1763–1766CrossRefPubMed
Zurück zum Zitat Silverberg GD et al (2003) Alzheimer’s disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol 2(8):506–511CrossRefPubMed Silverberg GD et al (2003) Alzheimer’s disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol 2(8):506–511CrossRefPubMed
Zurück zum Zitat Simon MJ, Iliff JJ (2016) Regulation of cerebrospinal fluid (CSF) flow in neurodegenerative, neurovascular and neuroinflammatory disease. Biochim Biophys Acta 1862(3):442–451CrossRefPubMed Simon MJ, Iliff JJ (2016) Regulation of cerebrospinal fluid (CSF) flow in neurodegenerative, neurovascular and neuroinflammatory disease. Biochim Biophys Acta 1862(3):442–451CrossRefPubMed
Zurück zum Zitat Sun X et al (2006) Hypoxia facilitates Alzheimer’s disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci 103(49):18727–18732CrossRefPubMedPubMedCentral Sun X et al (2006) Hypoxia facilitates Alzheimer’s disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci 103(49):18727–18732CrossRefPubMedPubMedCentral
Zurück zum Zitat Tapiola T et al (2009) Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66(3):382–389CrossRefPubMed Tapiola T et al (2009) Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66(3):382–389CrossRefPubMed
Zurück zum Zitat Thomas T et al (1996) β-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380(6570):168–171CrossRefPubMed Thomas T et al (1996) β-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380(6570):168–171CrossRefPubMed
Zurück zum Zitat Toombs J et al (2017) Effect of spinal manometers on cerebrospinal fluid amyloid-β concentration. J Alzheimer’s Dis 56(3):885–891CrossRef Toombs J et al (2017) Effect of spinal manometers on cerebrospinal fluid amyloid-β concentration. J Alzheimer’s Dis 56(3):885–891CrossRef
Zurück zum Zitat van Waalwijk van Doorn LJC et al (2017) Improved cerebrospinal fluid-based discrimination between Alzheimer’s disease patients and controls after correction for ventricular volumes. J Alzheimer’s Dis 56(2):543–555CrossRef van Waalwijk van Doorn LJC et al (2017) Improved cerebrospinal fluid-based discrimination between Alzheimer’s disease patients and controls after correction for ventricular volumes. J Alzheimer’s Dis 56(2):543–555CrossRef
Zurück zum Zitat Wallin AK et al (2010) CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 74(19):1531–1537CrossRefPubMed Wallin AK et al (2010) CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 74(19):1531–1537CrossRefPubMed
Zurück zum Zitat Whiteley W et al (2006) CSF opening pressure: reference interval and the effect of body mass index. Neurology 67(9):1690–1691CrossRefPubMed Whiteley W et al (2006) CSF opening pressure: reference interval and the effect of body mass index. Neurology 67(9):1690–1691CrossRefPubMed
Zurück zum Zitat Wostyn P, Audenaert K, De Deyn PP (2009) More advanced Alzheimer’s disease may be associated with a decrease in cerebrospinal fluid pressure. Cerebrospinal Fluid Res 6:14CrossRefPubMedPubMedCentral Wostyn P, Audenaert K, De Deyn PP (2009) More advanced Alzheimer’s disease may be associated with a decrease in cerebrospinal fluid pressure. Cerebrospinal Fluid Res 6:14CrossRefPubMedPubMedCentral
Zurück zum Zitat Zhang C, Saunders AJ (2007) Therapeutic targeting of the alpha-secretase pathway to treat Alzheimer’s disease. Discov Med 7(39):113–117PubMed Zhang C, Saunders AJ (2007) Therapeutic targeting of the alpha-secretase pathway to treat Alzheimer’s disease. Discov Med 7(39):113–117PubMed
Metadaten
Titel
Levels of amyloid-beta-42 and CSF pressure are directly related in patients with Alzheimer’s disease
verfasst von
Tommaso Schirinzi
Giulia Di Lazzaro
Giulia Maria Sancesario
Vito Luigi Colona
Eugenia Scaricamazza
Nicola Biagio Mercuri
Alessandro Martorana
Giuseppe Sancesario
Publikationsdatum
02.09.2017
Verlag
Springer Vienna
Erschienen in
Journal of Neural Transmission / Ausgabe 12/2017
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-017-1786-8

Weitere Artikel der Ausgabe 12/2017

Journal of Neural Transmission 12/2017 Zur Ausgabe

Neurology and Preclinical Neurological Studies - Original Article

Cerebrospinal fluid injection into adult zebrafish for disease research

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.